Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus
New York, NY– June 27, 2019. The Lupus Research Alliance (LRA) and clinical research affiliate, Lupus Therapeutics, broadened a collaboration with Bristol-Myers Squibb (BMS) to study the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN) – kidney damage affecting about 50 percent of people with lupus. This expands the existing collaboration in systemic lupus erythematosus (SLE). […] Read More